Hvsen Biotechnology (300871) Fundamentals 2026 — P/E 14.0x, Revenue Analysis | SniperIQ
Hvsen Biotechnology (300871) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥4.1B, trading at ¥20.31 on the SHZ. This SniperIQ fundamentals page covers Hvsen Biotechnology's valuation (P/E 14.0x, P/B 1.8x), profitability (net margin 16.5%), revenue (¥1.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hvsen Biotechnology's market cap?
Hvsen Biotechnology (300871) has a market capitalization of approximately ¥4.1B, trading at ¥20.31 on the SHZ. Market cap moves with the live share price.
What is Hvsen Biotechnology's P/E ratio?
Hvsen Biotechnology's trailing twelve-month P/E ratio is 14.0x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hvsen Biotechnology?
Hvsen Biotechnology runs a net profit margin of 16.5%, a gross margin of 33.7%, and an operating margin of 18.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hvsen Biotechnology generate?
Hvsen Biotechnology reported revenue of ¥1.7B for fiscal year 2025, with net income of ¥253M and earnings per share (EPS) of 1.25. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hvsen Biotechnology pay a dividend?
Hvsen Biotechnology offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hvsen Biotechnology financially healthy?
Hvsen Biotechnology carries a debt-to-equity ratio of 0.27x and a current ratio of 1.93x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hvsen Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hvsen Biotechnology (300871) the key facts are: market cap ¥4.1B, P/E 14.0x, revenue ¥1.7B, 52-week range 19.08-32.62. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hvsen Biotechnology's full fundamentals live
Get Hvsen Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.